3.8 Article

Abnormality Pattern of F-18 FDG PET Whole Body with Functional MRI Brain in Post-Acute COVID-19

Journal

NUCLEAR MEDICINE AND MOLECULAR IMAGING
Volume 56, Issue 1, Pages 29-41

Publisher

SPRINGER HEIDELBERG
DOI: 10.1007/s13139-021-00730-6

Keywords

Post-acute COVID-19; Long COVID-19; Inflammation; F-18 FDG PET; Fluorodeoxyglucose; Resting-state functional MRI

Ask authors/readers for more resources

This study investigated imaging abnormalities associated with post-acute COVID-19 using F-18 FDG PET/CT and PET/rsfMRI brain scans. The results showed that patients had myositis, vasculitis, and lung abnormalities, as well as brain connectivity abnormalities. The study suggests that whole body F-18 FDG PET can be a potential tool to assess inflammatory process and support the hyperinflammatory etiology in post-acute COVID-19.
Purpose The study aimed to investigate imaging abnormalities associated with post-acute COVID-19 using F-18 FDG PET/CT and PET/rsfMRI brain. Methods We retrospectively recruited 13 patients with post-acute COVID-19. The post-acute COVID-19 symptoms and neuropsychiatric tests were performed before F-18 FDG PET/CT whole body with PET/rsfMRI brain. Qualitative and semi-quantitative analyses were also conducted in both whole body and brain images. Results Among the 13 patients, 8 (61.5%) had myositis, followed by 8 (61.5%) with vasculitis (mainly in the thoracic aorta), and 7 (53.8%) with lung abnormalities.. Interestingly, one patient with a very high serum RBD IgG antibody demonstrated diffuse myositis throughout the body which potentially associated with immune-mediated myositis. One patient experienced psoriasis exacerbation with autoimmune-mediated after COVID-19. Most patients had multiple areas of abnormal brain connectivity involving the frontal and parieto-temporo-occipital lobes, as well as the thalamus. Conclusion The whole body F-18 FDG PET can be a potential tool to assess inflammatory process and support the hyperinflammatory etiology, mainly for lesions in skeletal muscle, vascular wall, and lung, as well as, multiple brain abnormalities in post-acute COVID-19. Nonetheless, further studies are recommended to confirm the results.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

3.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Radiology, Nuclear Medicine & Medical Imaging

Alterations in 18F-FDG PET/MRI and 15O-Water PET Brain Findings in Patients With Neurological Symptoms After COVID-19 Vaccination A Pilot Study

Dheeratama Siripongsatian, Anchisa Kunawudhi, Chetsadaporn Promteangtrong, Peerapon Kiatkittikul, Attapon Jantarato, Arthita Choolam, Krongkamol Ponglikitmongkol, Taweegrit Siripongboonsitti, Tharathorn Kaeowirun, Chanisa Chotipanich

Summary: This study investigated functional abnormalities in the brain of patients who experienced neurological adverse effects following COVID-19 vaccination. The results showed metabolic changes in multiple brain regions, which were related to anxiety.

CLINICAL NUCLEAR MEDICINE (2022)

Article Immunology

Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: A randomized controlled trial

Kriangkrai Tawinprai, Taweegrit Siripongboonsitti, Thachanun Porntharukchareon, Kasiruck Wittayasak, Nawarat Thonwirak, Kamonwan Soonklang, Gaidganok Sornsamdang, Chirayu Auewarakul, Nithi Mahanonda

Summary: This study evaluated the immunogenicity and safety of an intradermal fractional third dose of AZD1222 vaccine among individuals previously vaccinated with CoronaVac. The results showed that the fractional dose was non-inferior to the standard intramuscular third dose in terms of immunogenicity, with mostly mild to moderate adverse events.

VACCINE (2022)

Editorial Material Radiology, Nuclear Medicine & Medical Imaging

Discrepancy between [18F]-FES and [18F]-FDG PET/CT in ER-positive breast cancer with oesophageal metastasis

Peerapon Kiatkittikul, Chetsadaporn Promteangtrong, Anchisa Kunawudhi, Dheeratama Siripongsatian, Chanisa Chotipanich

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2022)

Article Biotechnology & Applied Microbiology

Persistence of immunogenicity, contributing factors of an immune response, and reactogenicities after a single dose of the ChAdOx1 (AZD1222) COVID-19 vaccine in the Thai population

Kriangkrai Tawinprai, Taweegrit Siripongboonsitti, Thachanun Porntharukchareon, Bothamai Dechates, Harnphadungkit Monprach, Gaidganok Sornsamdang, Kasiruck Wittayasak, Kamonwan Soonklang, Nithi Mahanonda

Summary: This study suggests that the immune response to a single dose of the AZD1222 vaccine remains stable for three months in the Thai population.

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2022)

Article Pharmacology & Pharmacy

Pharmacokinetic Comparison of Favipiravir Oral Solution and Tablet Formulations in Healthy Thai Volunteers

Taweegrit Siripongboonsitti, Teerapat Ungtrakul, Natcha Watanapokasin, Pornuma Timsri, Kawinthida Wongpakdee, Parin Wattanasin, Chiravi Pavitrapok, Ariya Khunvichai, Promporn Jamnongtanachot, Wunlapa Mueannoom, Tanya Kitpoka, Weena Arjharn, Nithi Mahanonda

Summary: This study compared the pharmacokinetics and safety of favipiravir oral solution and tablet formulations. The results showed bioequivalence between the two formulations, with the oral solution offering the advantage of easier swallowing for patients.

CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2023)

Article Infectious Diseases

Efficacy of combination therapy of fluvoxamine and favipiravir vs favipiravir monotherapy to prevent severe COVID-19 among mild to moderate COVID-19 patients: Open-label randomized controlled trial (EFFaCo study)

Taweegrit Siripongboonsitti, Teerapat Ungtrakul, Kriangkrai Tawinprai, Tararin Nimmol, Mullika Buttakosa, Gaidganok Sornsamdang, Tanadul Jarrusrojwuttikul, Phumin Silapant, Nithi Mahanonda

Summary: This study aimed to assess the immunomodulatory effects of fluvoxamine in patients with mild to moderate COVID-19. The results showed that the combination therapy of fluvoxamine and favipiravir did not provide significant benefits in preventing disease progression in these patients, but it resulted in lower hospitalization rates, oxygen supplemental rates, intensive care rates, and mortality rates.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2023)

Article Plant Sciences

Efficacy of Andrographis paniculata extract treatment in mild to moderate COVID-19 patients being treated with favipiravir: A double-blind, randomized, placebo-controlled study (APFaVi trial)

Taweegrit Siripongboonsitti, Teerapat Ungtrakul, Kriangkrai Tawinprai, Chirayu Auewarakul (Udomsakdi), Wipada Chartisathian (Kraikriangsri), Thitikan Jansala, Rattana Julsawad, Kamonwan Soonklang, Nithi Mahanonda, Chulabhorn Mahidol

Summary: The combination treatment of Andrographis paniculata extract (APE) and favipiravir did not provide additional clinical and virological benefits in patients with mild to moderate COVID-19. However, APE may have potential advantages in preventing severe COVID-19 by early reduction of IL-1 beta levels, which needs further investigation.

PHYTOMEDICINE (2023)

Article Medicine, General & Internal

The Real-World Clinical Outcomes of Favipiravir Treatment with Telemedicine Monitoring in Preventing Disease Progression in Mild to Moderate COVID-19 Patients; A Retrospective Cohort Study

Taweegrit Siripongboonsitti, Kriangkrai Tawinprai, Kunsuda Cheirsilpa, Teerapat Ungtrakul, Wasanai Krisorakun, Chanisa Chotipanich, Nat Wimolsiri, Permpen Noitun, Netnapis Srirattana, Nithi Mahanonda

Summary: This study aimed to assess the outcome of favipiravir treatment in preventing clinical deterioration in mild to moderate COVID-19 cases with adjunctive telemonitoring during the COVID-19 surge. The results showed that favipiravir treatment for mild to moderate COVID-19 cases in outpatient settings, coupled with telemonitoring, was both safe and effective in preventing clinical deterioration, including the need for oxygen supplementation.

MEDICINA-LITHUANIA (2023)

Article Radiology, Nuclear Medicine & Medical Imaging

Head-to-head comparison of 18F-FDG and 18F-FES PET/CT for initial staging of ER-positive breast cancer patients

Peerapon Kiatkittikul, Supanida Mayurasakorn, Chetsadaporn Promteangtrong, Anchisa Kunawudhi, Dheeratama Siripongsatian, Natdanai Hirata, Attapon Jantarato, Natphimol Boonkawin, Sukanya Yaset, Pattanapong Kongsakorn, Warunya Phewnual, Chanisa Chotipanich

Summary: The diagnostic performance of F-18-FES and F-18-FDG for initial staging of ER-positive breast cancer is comparable, but F-18-FES performs better for strongly ER-positive breast cancer. Combining F-18-FES and F-18-FDG may overcome the limitations of each tracer and achieve more accurate staging.

EUROPEAN JOURNAL OF HYBRID IMAGING (2023)

Article Microbiology

Efficacy of combined COVID-19 convalescent plasma with oral RNA-dependent RNA polymerase inhibitor treatment versus neutralizing monoclonal antibody therapy in COVID-19 outpatients: a multi-center, non-inferiority, open-label randomized controlled trial (PlasMab)

Taweegrit Siripongboonsitti, Nuttakant Nontawong, Kriangkrai Tawinprai, Ornpreya Suptawiwat, Kamonwan Soonklang, Yong Poovorawan, Nithi Mahanonda

Summary: This study demonstrates that high neutralizing titer COVID-19 convalescent plasma therapy (CPT) combined with favipiravir (FPV) is non-inferior to sotrovimab in preventing hospitalization and severe outcomes in outpatients with mild-to-moderate COVID-19 and high-risk comorbidities. It highlights the potential of CPT-FPV as an alternative to neutralizing monoclonal antibodies like sotrovimab, particularly for emerging variants with spike protein mutations. The study's unique approach comparing a monoclonal antibody with CPT shows the efficacy of early intervention using high neutralizing antibody titer CPT, even in populations with a significant proportion of elderly patients. These findings are crucial in addressing the treatment challenges posed by the rapidly mutating SARS-CoV-2 virus and the need for adaptable therapeutic strategies.

MICROBIOLOGY SPECTRUM (2023)

Article Public, Environmental & Occupational Health

The real-world effectiveness of fluvoxamine therapy in mild to moderate COVID-19 patients; A historical cohort study (Fluvoxa Trial)

Taweegrit Siripongboonsitti, Kriangkrai Tawinprai, Paruspak Payoong, Nithi Mahanonda

Summary: In mild to moderate COVID-19 patients, fluvoxamine treatment failed to demonstrate effectiveness in preventing disease deterioration and may lead to a higher incidence of pneumonia, hospitalization, and oxygen supplementation.

JOURNAL OF INFECTION AND PUBLIC HEALTH (2023)

Article Multidisciplinary Sciences

Favipiravir treatment in non-severe COVID-19: promising results from multicenter propensity score-matched study (FAVICOV)

Taweegrit Siripongboonsitti, Marisa Muadchimkaew, Kriangkrai Tawinprai, Ornisa Issaranon, Wichuda Meepholkij, Pureepat Arttawejkul, Apiradee Vararungzarit, Kaewklao Thavornwattana, Nithi Mahanonda

Summary: This study aimed to evaluate the efficacy of favipiravir (FPV) in preventing severe COVID-19 in patients with mild-to-moderate symptoms. The results showed that FPV treatment improved clinical outcomes and reduced the need for oxygen supplementation and hospitalization compared to standard treatment.

SCIENTIFIC REPORTS (2023)

Article Infectious Diseases

Effect of Inactivated SARS-CoV-2 Vaccines and ChAdOx1 nCoV-19 Vaccination to Prevent COVID-19 in Thai Households (VacPrevent trial)

Marisa Muadchimkaew, Taweegrit Siripongboonsitti, Saowanee Wongpatcharawarakul, Chanyapak Boonsankaew, Kriangkrai Tawinprai, Kamonwan Soonklang, Nithi Mahanonda

Summary: The study investigated the effectiveness of inactivated and ChAdOx1 nCoV-19 vaccination in preventing household transmission of SARS-CoV-2. The results showed that completing two doses of the SARS-CoV-2 vaccine within 14-90 days led to a significant reduction in household transmission. Wearing masks also played a role in reducing the risk of transmission.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2022)

No Data Available